{"id":"heterologous-boost-schedule","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach primes the immune system with one vaccine type (e.g., viral vector or protein subunit) and then boosts with a different platform targeting the same antigen, leveraging complementary immune pathways. This heterologous prime-boost strategy can generate stronger cellular and humoral immunity compared to homologous schedules, particularly useful for infectious disease and cancer vaccines.","oneSentence":"A heterologous boost schedule is a vaccination strategy that uses different vaccine platforms or antigens in sequential doses to enhance immune response breadth and durability.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:47:43.480Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 vaccination (heterologous prime-boost regimens)"},{"name":"Infectious disease prevention (general application)"}]},"trialDetails":[{"nctId":"NCT05054621","phase":"PHASE2","title":"Immunogenicity of COVID-19 Vaccine on Heterologous Schedule","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-09-15","conditions":"Covid-19, Vaccine, Immunogenicity","enrollment":100},{"nctId":"NCT05079633","phase":"PHASE4","title":"A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2021-09-30","conditions":"Covid19 Vaccine","enrollment":220},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":"Covid19","enrollment":360},{"nctId":"NCT05668065","phase":"PHASE3","title":"Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines","status":"COMPLETED","sponsor":"Institut Pasteur de Tunis","startDate":"2021-11-22","conditions":"COVID-19","enrollment":199},{"nctId":"NCT05087368","phase":"PHASE2","title":"Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2021-12-01","conditions":"Covid19","enrollment":520},{"nctId":"NCT03589807","phase":"PHASE2","title":"2013/2017 H7N9 Prime-Boost Interval","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-21","conditions":"Avian Influenza, Influenza Immunisation","enrollment":180},{"nctId":"NCT03141138","phase":"PHASE1","title":"Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine","status":"UNKNOWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2017-11-08","conditions":"Dengue Virus","enrollment":40},{"nctId":"NCT02601716","phase":"PHASE2","title":"PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2016-01","conditions":"Malaria","enrollment":92},{"nctId":"NCT02860650","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-08","conditions":"Healthy","enrollment":72},{"nctId":"NCT02325050","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-01-08","conditions":"Healthy","enrollment":164},{"nctId":"NCT02313077","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2014-12-17","conditions":"Healthy","enrollment":87},{"nctId":"NCT02376426","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-03","conditions":"Healthy","enrollment":72},{"nctId":"NCT02376400","phase":"PHASE1","title":"A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-04","conditions":"Healthy","enrollment":78},{"nctId":"NCT01397227","phase":"PHASE1, PHASE2","title":"A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-06","conditions":"Malaria","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Heterologous boost schedule","genericName":"Heterologous boost schedule","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"A heterologous boost schedule is a vaccination strategy that uses different vaccine platforms or antigens in sequential doses to enhance immune response breadth and durability. Used for COVID-19 vaccination (heterologous prime-boost regimens), Infectious disease prevention (general application).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}